

Product Data Sheet

Product Name: Orforglipron hemicalcium hydrate

Cat. No.: GC70336

Chemical Properties

Cas. No. 3008544-96-2


Formula $C_{48}H_{48}F_2N_{10}O_{5.1/2}Ca \cdot H_2O$ M.Wt 921.02

Solubility DMSO : 25 mg/mL (27.14 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) Storage 4°C, sealed storage, away from moisture

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure



Background

Orforglipron hemicalcium hydrate (LY3502970 hemicalcium hydrate; GLP-1 receptor agonist 1 hemicalcium hydrate) is the calcium salt hydrate form of Orforglipron . Orforglipron is an orally active agonist for Glucagon-like peptide-1 receptor (GLP-1R), which exhibits potency in ameliorating the type 2 diabete.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Orforglipron hemicalcium hydrate (0.94-4.8 nM in plasma concentration, i.v., or 0.05-0.1 mg/mL, i.g. for 5 days) suppresses food intake in a dose-dependent manner, promotes insulin secretion and blood glucose reduction in cynomolgus monkey model^[1].

Orforglipron hemicalcium hydrate (0.05-1.35 mg/kg, i.g.) reaches C_{max} 2 hours after administration at all doses, exhibits proportional ratio of increase in plasma drug exposure to dose increase, indicates a dose-dependent absorption in the gastrointestinal tract^[1].

Pharmacokinetic Analysis of Orforglipron hemicalcium hydrate in cynomolgus monkey ^[1]

route	Dose (mg/kg)	T _{max} (h)	C _{max} (ng/mL)	AUC _{0-24h} (ng·h/mL)
i.g.	0.05	2.0	4.78	23.7
i.g.	0.15	2.0	20.7	135
i.g.	0.45	2.0	32.0	208
i.g.	1.35	2.0	148	1040

References:

[1]. Pyrazolopyridine derivative having glp-1 receptor agonist effect. WO2018056453A1

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA